Increased IL-17A but decreased IL-27 serum levels in patients with multiple sclerosis
IJI-Iranian Journal of Immunology. 2013; 10 (1): 47-54
en En
| IMEMR
| ID: emr-142677
Biblioteca responsable:
EMRO
Effector CD4[+] T cell subsets play an important role in Multiple Sclerosis [MS]. Interleukin-27 [IL-27] suppresses Th [Th1, Th2 and Th17] cells and dampens autoimmunity and tissue inflammation by promoting the generation of Type 1 regulatory T cells [Tr1]. To identify the relative levels of IL-27 and IL-17A in MS disease. In a case-control study, venous blood was collected from forty MS patients and forty-three healthy subjects as control group. Serum levels of IL-27 and IL- 17A were measured by ELISA method. A significant difference between serum IL-17A concentration in patients [120.68 +/- 209.85 pg/ml] and control group [67.26 +/- 117.76 pg/ml, p=0.016] was found. Serum IL-27 levels of the MS patients [159.7 +/- 581.4 pg/ml] were significantly lower than control subjects [180.35 +/- 507.84 pg/ml, p=0.001]. Our findings show decreased levels of IL-27 against increasing IL-17A levels in patients group which may suggest the suppressive role of IL-27 on inflammatory process of MS
Buscar en Google
Índice:
IMEMR
Asunto principal:
Enfermedades Autoinmunes
/
Ensayo de Inmunoadsorción Enzimática
/
Estudios de Casos y Controles
/
Interleucina-27
/
Esclerosis Múltiple
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Iran. J. Immunol.
Año:
2013